Curriculum Vitae

Document Sample
Curriculum Vitae Powered By Docstoc
					                               Curriculum Vitae

                  MARK J. WOYSHVILLE, M.D. FAASM

                                    January 2010

                        North Star Medical Research, LLC
                                18660 Bagley Road
                               Building II, Suite 205
                          Middleburg Heights, OH 44130
                              Voice: (440) 234-5700
                               Fax: (440) 234-5710
                        mwoyshville@northstarresearch.org

CURRENT LICENSES, CERTIFICATIONS AND REGISTRATIONS

11/2007     Diplomate, Sleep Medicine, American Board of Medical Specialties
10/2007     Member, Sleep Research Society
10/2006     Fellow, American Academy of Sleep Medicine
9/21/05     Diplomate, Sleep Medicine, American Board of Sleep Medicine
6/19/95     Diplomate, Psychiatry, American Board of Psychiatry and Neurology
            Recertified July, 2005
2/14/92     State of Ohio, Medicine and Surgery Certificate, #35-06-3012
12/3/90     Drug Enforcement Administration, registration, practitioner, all schedules
7/1/90      Diplomate, National Board of Medical Examiners

POSTGRADUATE TRAINING AND ACADEMIC ACTIVITY

7/93-7/98   Case Western Reserve University
            Assistant Professor of Psychiatry
7/92-6/93   Case Western Reserve University/University Hospitals of Cleveland
            Mood Disorders Special Fellow
7/90-6/92   University of California, San Diego (UCSD), La Jolla, California
            Psychiatric residency
7/89-6/90   Cleveland Clinic Foundation, Cleveland, Ohio.
            Combined internship in psychiatry, medicine, and neurology

EDUCATION

9/85-6/89   University of Cincinnati College of Medicine, Cincinnati, Ohio
            M.D. awarded 6/89
1/84-6/85   University of California, San Diego, La Jolla, California
            Post-baccalaureate work in chemistry, biology, and mathematics
9/76-6/82   Cleveland State University, Cleveland, Ohio
            B.S. (Physics), awarded Magna Cum Laude, 6/82
Curriculum Vitae: Mark J. Woyshville MD FAASM                                          January 2010


CLINICAL, ADMINISTRATIVE, AND SUPERVISORY ACTIVITY

4/07 to           North Star Medical Research LLC
present           CEO and Medical Director

                  North Star Medical Research engages in research at all levels of therapeutics
                  development, including proof-of-concept and investigator-initiated studies. Of
                  special interest are neurologic, psychiatric, and sleep disease entities.

8/07 to           Central Ohio Mental Health
2/09              Psychiatrist

                  Providing psychiatric care to children, adolescents, adults, and elders at a semi-
                  rural community mental health center.

1/06 to           Cleveland Neuro-Sleep Research Institute, Inc.
4/07              Medical Director

                  The Institute was engaged in research involving sleep and neuropsychiatry, as
                  well as rheumatologic, endocrine, and cardiovascular conditions, among others.

7/01 to           Co-Director, Southwest Cleveland Sleep Center
4/07              Director, Neuropsychiatric Sleep Medicine Program

                  The Center’s mission focuses on the evaluation and management of sleep
                  disorders of all kinds, with an emphasis on comorbid sleep and
                  neuropsychopathology.

7/00 to           Disability and Forensic Evaluator
present
                  Provide impartial and thorough independent medical and forensic evaluations
                  bearing on the issues of causality and impairment related to industrial injury
                  claims, as well as determining Competency to Stand Trial and Sanity at the
                  Time of the Act.

10/97 to          Private Practice of General Psychiatry
present
                  Provide consultation, evaluation, and management services to individuals and
                  organizations, specializing in the psychodynamic and psychopharmacologic
                  treatment of clergy, religious, and secular professionals.

1/00–6/01         Psychiatrist, Ohio Department of Rehabilitation and Corrections
7/04–7/05
                  Attending psychiatrist treating the seriously and persistently mentally ill in a
                  State custody facility; and the dually-diagnosed mentally ill in a privately-
                  contracted State custody setting.

                                                2 of 12
Curriculum Vitae: Mark J. Woyshville MD FAASM                                         January 2010


6/01–4/04         Forensic Psychiatrist, Ohio Department of Mental Health

                  Attending Psychiatrist on an inpatient Restoration to Competency unit,
                  providing clinical care, forensic evaluations, and expert testimony.

5/00–2/01         Psychiatrist, Family Focus Center

                  Attending psychiatrist, treating mentally ill children and adolescents in a
                  community mental health setting.

11/98–1/00        Psychiatrist, W.G. Nord Center

                  Attending psychiatrist at a large, urban community mental health center,
                  providing the full spectrum of psychiatric services, with an emphasis on
                  treating the seriously and persistently mentally ill.

3/97-9/97         Attending Psychiatrist, Veteran’s Addictions Recovery Center, VAMC

                  Responsibilities included providing the full spectrum inpatient and outpatient
                  dual-diagnosis assessment and management. Specialized in the treatment of
                  veterans suffering with substance use disorders in the context of severe mental
                  illness. 70% effort.

3/97–9/97         Research Psychiatrist, Veteran’s Addictions Recovery Center, VAMC

                  Participated in research quantifying affect in dually diagnosed (addictive
                  disorder plus other mental illness) veterans with “high negative affect,” using
                  the measures and methods of chaos theory. 30% effort.

7/93-3/97         Assistant Professor of Psychiatry, Case-Western Reserve University:

                  Provided teaching and supervision in psychopharmacologic and psychodynamic
                  psychiatry for residents individually and as a class; initiated and conducted the
                  Psychodynamic Psychiatry Seminar series; performed pre-clinical and clinical
                  medical student teaching. As the Director of the Clinical Drug Trials Unit of
                  the Mood Disorders Program, provided all Director services to the six research
                  personnel (one fiscal administrator, one clinical administrator, and four
                  research assistants) in the Mood Disorders Research Program; led and directed
                  weekly consensus and inter-rater reliability meetings; responsible for nurturing
                  the research culture of the Program.

                  Founding physician of the Partial Hospitalization Program and its first full-
                  time, regular attending. Worked closely with Administration to support and
                  direct the growth of the Program, while supervising and teaching all disciplines.



                                                3 of 12
Curriculum Vitae: Mark J. Woyshville MD FAASM                                       January 2010


7/93-3/97         Assistant Professor of Psychiatry, Case-Western Reserve University, continued:

                  Attending on the Hanna Pavilion 4 Adult Inpatient Psychiatric Unit, responsible
                  for providing attending leadership for an inpatient interdisciplinary team,
                  treating the full spectrum of adult psychopathology emphasizing mood
                  disorders, schizophrenia, and borderline personality disorder. Provided
                  inpatient and outpatient ECT services. Supervised and taught, all disciplines.

FELLOWSHIPS, ELECTIVES, AWARDS, SPECIAL QUALIFICATIONS

7/95              Special Dedication Award for teaching, presented by Case Western Reserve
                  psychiatric residents

7/92-6/93         Mood Disorders Research Fellow with special emphasis on the management of
                  treatment-resistant affective disorders utilizing psychopharmacology and
                  electroconvulsive therapy.

3/89-5/89         Clinical Research Elective in “Computers in Clinical Medicine,”
                  National Institutes of Health, Bethesda, Maryland.

6/86-9/86         Dean’s Office Summer Research Fellowships,
6/85-9/85         University of Cincinnati College of Medicine.

ACADEMIC RESEARCH
Peer Reviewed Research:

7/94-7/98         Case Western Reserve University/University Hospitals of Cleveland

                  Principal Investigator, "Affective Instability: Quantification,
                  Conceptualization, and Clinical Significance."
                  Funding: National Alliance for Research on Schizophrenia and Depression
                  (NARSAD) Young Investigator Award, $60,000.

3/95-9/96         Case Western Reserve University/University Hospitals of Cleveland
                  Mood Disorders Program

                  Co-Investigator in a maintenance study comparing valproate and lithium in
                  bipolar rapid cycling.
                  Funding: National Institute of Mental Health; The Stanley Foundation.

Unrestricted Educational Grants:

7/96-7/98         Case Western Reserve University/University Hospitals of Cleveland
                  Recipient, Wyeth-Ayerst Unrestricted Educational Grant, in support of
                  theoretical and phenomenological work in affective disorders.

                                                4 of 12
Curriculum Vitae: Mark J. Woyshville MD FAASM                                          January 2010


Investigator-Initiated Research:

7/07- 6/09          North Star Medical Research LLC:

                    Principal Investigator in a double-blind, placebo-controlled randomized clinical
                    trial (RCT) of a dopamine agonist in the management of restless legs syndrome
                    (RLS) in patients treated with serotonergically-active antidepressants.

1/09 to             North Star Medical Research LLC:
present
                    Principal Investigator in an open-label study of Amitiza (lubiprostone) for the
                    management of psychotropic-induced constipation.

Industry Sponsored Research:

North Star Medical Research, LLC

          A phase IIb, randomized, double-blind, two-arm, multi-center, placebo-controlled, study
          to assess the efficacy and safety of EN3224 (axomadol) in subjects with moderate to
          severe chronic low back pain.

          A double-blind, efficacy and safety study of duloxetine versus placebo in the treatment of
          children and adolescents with major depressive disorder.

          A prospective, randomized, active-controlled, rater-blinded study of the prevention of
          relapse comparing paliperidone palmitate with oral risperidone in adults with recently-
          diagnosed schizophrenia who are at high risk of relapse.

          A phase II, multicenter, randomized, double-blind, parallel group, placebo-controlled
          exploratory efficacy and safety study of SPD489 in adults 18-55 years with major
          depressive depressive disorder (MDD) as augmentation therapy to an antidepressant.

          A 12 week, randomized, double-blind, placebo-controlled, parallel-group, fixed dosage,
          study to evaluate the efficacy and safety of armodafinil as treatment for patients with
          excessive sleepiness associated with mild or moderate closed traumatic brain injury.

          A phase II, multicenter, randomized, double-blind, placebo-controlled study of the safety
          and efficacy of OPC-34712 as adjunctive therapy in the treatment of patients with major
          depressive disorder.

          Continuation Study – A phase II, multicenter, open-label study to assess the safety and
          tolerability of oral OPC-34712 as adjunctive therapy in adult patients with major
          depressive disorder.




                                                5 of 12
Curriculum Vitae: Mark J. Woyshville MD FAASM                                         January 2010


       A 52-week, multicenter, open-label study to evaluate the effectiveness of aripiprazole
       intramuscular depot as maintenance treatment in patients with schizophrenia “aspire
       open-label” (aripiprazole intramuscular depot program in schizophrenia).”

       A multi-center, randomized, placebo-controlled, double-blind, parallel group, efficacy
       and safety study of AZD7325 in the treatment of generalized anxiety disorder (GAD).
       A 3-arm, double-blind, placebo controlled clinical trial to assess the efficacy, safety and
       tolerability of pagoclone for the adult treatment of adults with stuttering.

       A randomized double blind placebo controlled four week study of the efficacy and safety
       of four doses (0.05 mg, 0.1 mg, 0.25 mg, 0.5 mg) of aplindore mr tablets vs. placebo in
       idiopathic restless legs syndrome.

       A phase III, double-blind, randomized, efficacy and safety study comparing the TAK-491
       plus chlorthalidone fixed dose combination vs benicar HCT® (olmesartan medoxomil-
       hydrochlorothiazide) in subjects with moderate to severe essential hypertension.

       A randomized, double-blind, parallel-group, placebo controlled, duloxetine-referenced,
       fixed dose study comparing the efficacy and safety of LuAA21004 in acute treatment of
       major depressive disorder in elderly patients.

       A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the
       efficacy and safety of armodafinial at a target dosage of 200 mg/day as treatment for
       adults with excessive sleepiness associated with obstructive sleep apnea/hypopnea
       syndrome with cormorbid major depressive disorder or dysthymic disorder.

       A randomized, double-blind, placebo-controlled subjective study to access the efficacy of
       APD125 in patients with primary insomnia characterized by difficulty maintaining sleep.

       A randomized, double-blind, parallel-group, placebo-controlled, fixed dose study
       comparing the efficacy and safety of 2 doses of LuAA21004 in acute treatment of adults
       with generalized anxiety disorder (GAD).

       A double-blind, randomized, placebo and active-controlled, multi-center study examining
       the efficacy and safety of SEP-225441 in subjects with generalized anxiety disorder
       (GAD).

       A year-long, open-label, multicenter study of the safety and efficacy of vilazodone in
       subjects with major depressive disorder.

       A multicenter, double-blind, randomized, placebo-controlled study examining the safety,
       efficacy, and tolerability of SEP-225289 in subjects with major depressive disorder
       (including atypical and melancholic features).




                                                6 of 12
Curriculum Vitae: Mark J. Woyshville MD FAASM                                       January 2010


       A multicenter, multiple dose, double-blind, randomized, placebo-controlled, parallel
       group study of the safety and efficacy of AGN 203818 in female patients with
       fibromyalgia syndrome.

Cleveland Neuro-Sleep Research Institute, Inc.

       A phase III pivotal, multi-center, double-blind, randomized, placebo-controlled mono-
       therapy study of milnacipran for treatment of fibromyalgia.

       A long-term study of XP13512 vs. placebo treatment assessing maintenance of efficacy
       and safety in patients with restless legs syndrome.

       A 6-month, phase 3, randomized, double-blind, parallel-group, controlled, multi-center
       study to evaluate the incidence of gastric ulcers following administration of either PN 200
       or naproxen in subjects who are at risk for developing NSAID-associated ulcers.

       A multi-centre, double-blind, randomised-withdrawal, parallel-group, placebo-controlled
       phase III study of the efficacy and safety of quetiapine fumarate sustained release
       (Seroquel SR™) as monotherapy in the maintenance treatment of patients with major
       depressive disorder following an open-label stabilisation period (amethyst study).

       A multi-center, double-blind, randomized-withdrawal, parallel-group, placebo-controlled
       phase III study of the efficacy and safety of quetiapine fumarate sustained release
       (Seroquel SR™) as monotherapy in the maintenance treatment of patients with
       generalized anxiety disorder following an open-label stabilization period (platinum
       study).

       A comparison of zolpidem tartrate extended-release vs. placebo in the treatment of
       insomnia associated with newly diagnosed major depressive disorder (MDD) or untreated
       MDD relapse, when used concomitantly with escitalopram.

       A comparison of zolpidem tartrate extended-release vs. placebo in the treatment of
       insomnia associated with generalized anxiety disorder (GAD) when used concomitantly
       with escitalopram.

       A 28 day, polysomnographic and subjective assessment of GW679769, 10 and 30 mg, for
       the treatment of primary insomnia: A randomized, double-blind, parallel-group, placebo-
       controlled trial.

       A 52-Week, open-label study to assess the long-term safety of ropinirole extended release
       (XR) in patients with restless legs syndrome (RLS).

       A randomized, double-blind, placebo-controlled, safety and efficacy study of Xyrem®
       (sodium oxybate) in subjects with fibromyalgia.

       A long-term, open-label safety and efficacy study of Xyrem® (sodium oxybate) in
       subjects with fibromyalgia.
                                                7 of 12
Curriculum Vitae: Mark J. Woyshville MD FAASM                                      January 2010



Southwest Cleveland Sleep Center

       A phase 2, double-blind, randomized, placebo-controlled, parallel-group, multicenter,
       proof-of-concept study to evaluate the safety and efficacy of Rozerem ™ taken in
       combination with gabapentin for the treatment of subjects with chronic insomnia.

       A randomized, double-blind, placebo-controlled, 3-way cross-over study to evaluate
       effects of APD125 in patients with insomnia.

       A phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter
       study to assess the long term efficacy and safety of doxepin HCl in primary elderly
       insomnia patients with sleep maintenance difficulties.

       Efficacy and safety of eplivanserin 5 mg/day on sleep maintenance insomnia: a 12-week
       multicenter, randomized, double-blind, placebo-controlled study followed by an open
       treatment phase extension with eplivanserin for 40 weeks period.

       The efficacy of eszopiclone 3 mg as adjunctive therapy in subjects with insomnia related
       to generalized anxiety disorder (GAD).

       A double-blind, randomized, placebo-controlled, multicenter, 30-night polysomnographic
       study of MK-0928 in adult patients with insomnia.

       A double-blind, randomized, placebo-controlled, multicenter, 30-night polysomnographic
       study of MK-0928 in elderly patients with insomnia.

       A 12 week, double-blind, placebo controlled, parallel group study to assess the efficacy
       and safety of Ropinirole XR (extended release) in patients with restless legs syndrome.

       Randomized, double-blind, positive-controlled, multicenter study comparing the efficacy
       of carvedilol phosphate modified release formulation (Coreg™ MR) and metoprolol
       succinate extended release (Toprol-XL®) on the reduction of microalbuminuria in
       patients with hypertension and microalbuminuria.

       A 12 month open-label, flexible-dosage (100-250 mg/day) extension study of the safety
       and efficacy of cep-10953 in the treatment of patients with excessive sleepiness
       associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, or chronic shift
       work sleep disorder.

       Randomized, double-blind, placebo-controlled, parallel-group, multi-center trial
       comparing the effects of orally administered Xyrem (sodium oxybate) with placebo for
       the treatment of fibromyalgia.




                                                8 of 12
Curriculum Vitae: Mark J. Woyshville MD FAASM                                        January 2010


       A 12-week, randomized, double-blind, placebo-controlled, parallel-group study to
       evaluate the efficacy and safety of cep-10953 (150 mg/day) as treatment for adults with
       residual excessive sleepiness associated with obstructive sleep apnea/hypopnea
       syndrome.

       Randomized, double-blind, placebo controlled, parallel-group, multi-center trial
       comparing the effects of orally administered Xyrem ® (sodium oxybate) with placebo for
       the treatment of narcolepsy.

       Randomized, double-blind, double-dummy, placebo-controlled, parallel-group, multi-
       center trial comparing the effects of orally administered Xyrem (sodium oxybate) with
       modafinil with placebo for the treatment of daytime sleepiness in narcolepsy.

Case Western Reserve University/University Hospitals of Cleveland Mood Disorders Program:

       A study investigating the antimanic efficacy of the anticonvulsant gabapentin
       (Neurontin), which is thought to act by blocking the uptake of GABA by the neuroglia
       and by inhibiting the synthesis of excitatory amino acids.

       A study comparing the rate of onset of antidepressant action of venlafaxine (Effexor) vs.
       fluoxetine (Prozac) in major depression.

       Clinical trials of lamotrigine (Lamictal), an anticonvulsant which acts by antagonizing
       sodium channel mediated excitatory neurotransmitter release, in the management of
       bipolar disorder.

       A double-blind, placebo-controlled study of the safety and efficacy of paroxetine (Paxil)
       vs. imipramine in bipolar depression.

       Double-blind maintenance study comparing valproate to lithium and placebo in the
       treatment of bipolar disorder.

       A study evaluating the efficacy of clozapine (Clozaril) in the treatment of refractory
       bipolar mood disorder and schizoaffective disorder, bipolar subtype.

       A study comparing amesergide, a novel 5-HT type 2 antagonist, to placebo and fluoxetine
       in the treatment of depression.

       Dose-finding study researching roxindole, a novel agent with D-2 autoreceptor and 5-HT
       type 1A agonist activities, and 5-HT re-uptake blockade action, in comparison with
       placebo in the treatment of depression.




                                                9 of 12
Curriculum Vitae: Mark J. Woyshville MD FAASM                                      January 2010


Pre-doctoral Research:

3/89-5/89         National Institutes of Health, National Library of Medicine,
                  Artificial Intelligence Branch.

                  Designed and implemented a utility in Prolog (an artificial intelligence
                  programming language) to facilitate the assignment of Medical Subject
                  Headings to nodes in the National Library of Medicine Semantic Network.
                  Funding: National Institutes of Health

6/86-5/89         University of Cincinnati College of Medicine
                  Division of Geriatrics/Alzheimer’s Research Center

                  Investigated EEG changes in Alzheimer’s dementia using the fractal dimension
                  as a quantifier. Researched the relationship between non-linear metric studies
                  on the EEG and clinical grades of severity in the dementias.
                  Funding: University of Cincinnati College of Medicine

6/85-5/89         University of Cincinnati College of Medicine
                  Division of Pharmacology and Cell Biophysics

                  Researched mathematical models capable of simulating certain aspects of
                  neuronal behavior. This work involved investigations of model nonlinear
                  dynamical systems using analog computers.
                  Funding: University of Cincinnati College of Medicine

11/84-6/85        University of California, San Diego, School of Medicine.
                  Laboratory of Biological Dynamics and Theoretical Medicine

                  Expanded the capabilities of the laboratory to include analog computation for
                  solving nonlinear differential equations by continuous time-domain integration.
                  Funding: University of California, San Diego, School of Medicine.

PUBLICATIONS

Peer Reviewed Publications:

Woyshville MJ, Ahmed M. Insomnia: An Overview. (Review Article). Indian Journal of Sleep
Medicine (IJSM) 2006; 1(3).

Woyshville MJ, Lackamp JM, Eisengart JA, Gilliland JAM. On the meaning and measurement
of affective instability: Clues from chaos theory. (Original Paper). Biological Psychiatry 1999;
45(3):261-269.




                                                10 of 12
Curriculum Vitae: Mark J. Woyshville MD FAASM                                     January 2010


Gordon RT, Cantor RJ, Woyshville MJ. A new chaos-based approach to data conceptualization.
(Article) In: Dagli CH, Akay M, Chen CL, Fernandez BR, Ghosh J, eds. Intelligent Engineering
Systems Through Artificial Neural Networks, Vol 6, ASME press, New York, 1996.

Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine in treatment refractory mania.
(Article). American Journal of Psychiatry 1996;153:759-764.

Calabrese JR, Fatemi SH, Kujawa M, Woyshville MJ. Predictors of differential response to
mood stabilizers. (Article). Journal of Clinical Psychopharmacology 1996. 16[2 suppl 1]:24S-
31S.

Calabrese JR, Woyshville MJ. Lithium therapy: Limitations and alternatives in the treatment of
bipolar disorders. (Article). Annals of Clinical Psychiatry 1995;7(2):103-112.

Calabrese JR, Woyshville MJ. A medication algorithm for treatment of rapid cycling?
(Article). Journal of Clinical Psychiatry 1995;5[suppl 3]:11-18.

Kimmel SE, Calabrese JR, Woyshville MJ, Meltzer HY. Clozapine in treatment refractory
mood disorders. (Article). Journal of Clinical Psychiatry 1994; 55(supplement B):91-93.

Woyshville MJ, Calabrese JR. Quantification of occipital EEG changes in Alzheimer’s disease
utilizing a new metric: The fractal dimension. (Article). Biological Psychiatry 1994; 35(6):381-
387.

Calabrese JR, Woyshville MJ, Kimmel SE, and Rapport DJ. Mixed states and bipolar rapid
cycling and their treatment with valproate. (Article). Psychiatric Annals 1993; 23(2):70-78.

Calabrese JR, Woyshville MJ, Kimmel SE, and Rapport DJ. Predictors of valproate response in
bipolar rapid cycling. (Brief Report). Journal of Clinical Psychopharmacology 1993; 13(4):280-
283.

Calabrese JR, Rapport DJ, Kimmel SE, Reece B, and Woyshville MJ. Rapid cycling bipolar
disorder and its treatment with valproate. (Article). Canadian Journal of Psychiatry. 1993;
38:45-51.

Abstracts:

Calabrese JR, Woyshville MJ, Bowden C, et al: Spectrum of efficacy of lamotrigine in
treatment-refractory manic depression. Presented at the Second International Conference on
Affective Disorders. Jerusalem, Israel. September 4-8, 1995

Letters:

Calabrese JR, Fatemi SH, Woyshville MJ: Antidepressant effects of lamotrigine in rapid
cycling bipolar disorder. Am J Psychiatry 1996;153(9):1236.



                                                11 of 12
Curriculum Vitae: Mark J. Woyshville MD FAASM                                 January 2010


Book Chapters:

Calabrese JR, Bowden CL, McElroy S, Cookson J, Andersen J, Rhodes L, Woyshville MJ, Keck
P, Kundu S, Paterson G, Ascher J, Bolden-Watson, C. Efficacy of lamotrigine in bipolar
disorders: Preliminary data on the affective disorders. In: Manji H, Bowden C, Belmaker R,
eds. Mechanisms Of Antibipolar Disorder Treatments: Focus On Lithium, Valproate, And
Carbamazepine. Washington DC: American Psychiatric Press; 1997.

Calabrese JR, Fatemi SH, Woyshville MJ. Diagnosis and treatment of rapid cycling bipolar
disorder. In: Dunner DL, ed. Current Psychiatric Therapy II. W.B. Saunders Co. 1997.

Calabrese JR, Bowden C, Woyshville MJ. Lithium and anticonvulsants in bipolar disorder. In:
Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. Raven
Press, Inc. NY, NY. 1995

Calabrese JR, Woyshville MJ, Rapport DJ. Clinical efficacy of valproate. In: Joffe RT,
Calabrese JR, eds. Anticonvulsants in Mood Disorders. Marcel Dekker, Inc. NY, NY. 1994.

CME Publications:

Calabrese JR, Woyshville MJ. Diagnosis and treatment of rapid-cycling bipolar disorder.
(Lesson). Directions in Psychiatry 1994; 14(16).




                                                12 of 12

				
DOCUMENT INFO
Shared By:
Categories:
Tags:
Stats:
views:14
posted:8/11/2011
language:English
pages:12